All In Biotech

Drug Trial Radar · NCT07285785

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

A Randomized, Open-Label Study to Assess Pharmacokinetics of Xifaxan® 200 mg in Pediatric Subjects 6 to 11 Years of Age With Acute Diarrhea of Suspected Bacterial Etiology, and the Safety and Efficacy of Xifaxan® 200 mg Plus Oral Rehydration Therapy (ORT) Compared to ORT Alone

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Feb 11, 2026

Primary completion

Apr 20, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria. It will also learn about the safety and effectiveness of rifaximin when given with oral rehydration therapy (ORT) compared with ORT alone. The main questions it aims to answer are: How does rifaximin 200 mg move through and leave the body in children with acute diarrhea? Is rifaximin safe for children in this age group? Does rifaximin plus ORT help resolve diarrhea faster than ORT alone? Researchers will compare rifaximin plus ORT to ORT alone to see if adding rifaximin improves outcomes. Participants will: Take one rifaximin 200 mg tablet + ORT three times a day for 3 days or receive ORT alone Receive oral rehydration therapy according to the investigator's standard of care Attend up to 4 clinic visits over 5 days and receive 4 follow-up phone calls Provide blood samples on Day 1 and Day 3 for pharmacokinetic testing (rifaximin group only) Provide stool samples to identify bacterial pathogens Keep a diary of stool frequency and consistency to help determine when diarrhea resolves Be monitored for side effects, vital signs, and laboratory changes

Conditions

  • Diarrhea
  • Gastroenteritis
  • Bacterial Infection
  • Acute Diarrhea

Interventions

  • Rifaximin 200 mg TabletDrug

    Participants receive rifaximin 200 mg tablets orally three times daily (TID) for 3 days in combination with oral rehydration therapy (ORT). Blood samples for pharmacokinetic analysis are collected on Day 1 and Day 3 at pre-dose, 1 hour post-dose, and 6 to 8 hours post-dose.

  • Oral Rehydration Therapy (ORT)Other

    Participants receive oral rehydration solution according to the investigator's standard of care. This is administered either alone (for the ORT-alone arm) or in combination with rifaximin (for the rifaximin + ORT arm). Participants or caregivers complete a daily diary documenting stool frequency, stool consistency, and related symptoms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak Plasma Concentration (Cmax) of RifaximinTime frame: Days 1 and 3
  2. Time to Maximum Plasma Concentration (Tmax) of RifaximinTime frame: Days 1 and 3
  3. Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last) for RifaximinTime frame: Days 1 and 3
  4. Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-τ) for RifaximinTime frame: Days 1 and 3
  5. Proportion of participants with Clinical CureTime frame: Up to Day 5 (End of Treatment)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Alliance Research Institute

    Lynwood, California · Recruiting

  • Direct Helpers

    Hialeah, Florida · Recruiting

  • SouthCoast Research Center

    Miami, Florida · Recruiting

  • Oceane7 Medical & Research Center, Inc

    Miami, Florida · Recruiting

  • Rophe Adult & Pediatric Medicine

    Union City, Georgia · Recruiting

  • Innovative Clinical Research Center

    Island Lake, Illinois · Recruiting

  • Cyn3rgy Research Corporation

    Gresham, Oregon · Recruiting

  • Little Stars Pediatrics / Tattva Trials

    Prosper, Texas · Recruiting

  • LinQ Research

    Rosharon, Texas · Recruiting

  • Tekton Research

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.